Kindred Biosciences

Our goal is to save lives and relieve suffering for the animals in our lives. We bring a determination and dedication to unite our expertise and research creativity in developing humane, effective, and safe therapies for our animal companions that people enjoy today. We are veterinary therapeutics, redefined. As one of the first pet biotech companies in the world, we understood early that to quickly deliver veterinary therapeutics in unmet and under served areas we needed a revolutionary approach. By leveraging the similarities between human and pet diseases, we are creating cutting edge versions of successful human drugs and biologics. Our belief is that this can substantially increase success rate and reduce time to market – increasing the quality of life for the pets with whom we share so much of our lives, providing the veterinary community with innovative treatment options, and, we anticipate, generating solid returns for our investors.
Burlingame, US
Size (employees)
41 (est)+6%
Kindred Biosciences was founded in 2013 and is headquartered in Burlingame, US

Kindred Biosciences Office Locations

Kindred Biosciences has an office in Burlingame
Burlingame, US (HQ)
200 1555 Old Bayshore Hwy

Kindred Biosciences Data and Metrics

Kindred Biosciences Financial Metrics


Net income (FY, 2016)

(5.8 m)

EBIT (FY, 2016)

(5.9 m)

Market capitalization (27-Jun-2017)

198.1 m

Closing share price (27-Jun-2017)


Cash (31-Dec-2016)

6.7 m
Kindred Biosciences's current market capitalization is $198.1 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

3.5 m

General and administrative expense

2.4 m

Operating expense total

5.9 m


(5.9 m)

Interest income

101 k

Net Income

(120 k)(27.1 m)(5.8 m)
USDFY, 2014FY, 2015FY, 2016


13 m20 m6.7 m


1.9 m1.8 m

Current Assets

101.5 m73.8 m58 m


394 k1.2 m2.4 m

Total Assets

101.9 m79.6 m61.6 m

Accounts Payable

420 k717 k410 k

Current Liabilities

2.9 m3.2 m3.9 m

Additional Paid-in Capital

130.5 m135 m138.8 m

Retained Earnings

(31.5 m)(58.6 m)(81.1 m)

Total Equity

76.4 m57.7 m

Financial Leverage

1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(120 k)(27.1 m)(5.8 m)

Depreciation and Amortization

146 k155 k


(14.1 m)16 m(37.9 m)

Accounts Payable

6 k30 k(710 k)

Cash From Operating Activities

(62 k)(22.8 m)(18.8 m)

Purchases of PP&E

(729 k)(952 k)

Cash From Investing Activities

29.4 m5.3 m

Cash From Financing Activities

1 m343 k162 k
Y, 2016

Financial Leverage

1.1 x

Kindred Biosciences Market Value History

Kindred Biosciences Online and Social Media Presence

Kindred Biosciences Company Life and Culture

You may also be interested in